Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,21404570,Cmax,"Cmax was 240.8 +/- 65.9 microIU/ml, Tmax was 28.75 +/- 14.21 hr after the first SKG-02 injection, and AUC was 11,414 +/- 3,462 microIU hr/ml in 9 patients evaluable for pharmacokinetics.","[Assessment of the efficacy, safety and pharmacokinetics of SKG-02 (recombinant human TSH) in postoperative diagnosis of well-differentiated thyroid cancer--a Japanese prospective, controlled, multicenter open-label study]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21404570/),[μiu] / [ml],240.8,112868,DB00024,Thyrotropin Alfa
,21404570,Tmax,"Cmax was 240.8 +/- 65.9 microIU/ml, Tmax was 28.75 +/- 14.21 hr after the first SKG-02 injection, and AUC was 11,414 +/- 3,462 microIU hr/ml in 9 patients evaluable for pharmacokinetics.","[Assessment of the efficacy, safety and pharmacokinetics of SKG-02 (recombinant human TSH) in postoperative diagnosis of well-differentiated thyroid cancer--a Japanese prospective, controlled, multicenter open-label study]. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21404570/),h,28.75,112869,DB00024,Thyrotropin Alfa
,21404570,AUC,"Cmax was 240.8 +/- 65.9 microIU/ml, Tmax was 28.75 +/- 14.21 hr after the first SKG-02 injection, and AUC was 11,414 +/- 3,462 microIU hr/ml in 9 patients evaluable for pharmacokinetics.","[Assessment of the efficacy, safety and pharmacokinetics of SKG-02 (recombinant human TSH) in postoperative diagnosis of well-differentiated thyroid cancer--a Japanese prospective, controlled, multicenter open-label study]. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21404570/),[h·μiu] / [ml],"11,414",112870,DB00024,Thyrotropin Alfa
